CB-5083 (SKU B6032): Precision p97 Inhibition for Oncology A

Reproducibility in cell viability and protein homeostasis assays is a persistent challenge, particularly when targeting complex ATPase-driven protein degradation pathways. Inconsistent apoptosis induction, variable cytotoxicity thresholds, and ambiguous dose-response curves often stem from off-target effects or poorly characterized inhibitors. CB-5083 (SKU B6032), a highly selective and orally bioavailable p97 inhibitor supplied by APExBIO, addresses these pain points by enabling precise perturbation of the p97/valosin-containing protein (VCP) axis. In this article, I detail real-world laboratory scenarios where CB-5083 offers data-backed solutions, guiding researchers in protocol optimization, experimental design, and product selection for robust oncology and protein homeostasis research.

What makes p97 inhibition with CB-5083 superior for modeling protein homeostasis disruption?

Scenario: A research group observes unpredictable results in their cell-based assays when using general proteasome inhibitors to study protein quality control and ER-associated degradation (ERAD) mechanisms.

Analysis: Many laboratories rely on broad-spectrum proteasome inhibitors, which can trigger off-target effects and obscure the specific role of p97 in protein homeostasis. This lack of selectivity often compromises both mechanistic clarity and assay reproducibility, especially in models requiring the precise disruption of ERAD or the unfolded protein response (UPR).

Answer: CB-5083 is a potent, selective p97 inhibitor that targets the second ATPase domain of p97 with an IC50 of 15.4 nM, as detailed in the product information. Unlike proteasome inhibitors, CB-5083 enables focused disruption of p97-mediated protein extraction and degradation, inducing a dose-dependent accumulation of poly-ubiquitinated proteins and triggering apoptosis in cancer cell lines. This precision makes it the preferred tool for dissecting protein homeostasis and ERAD, as highlighted by its application in studies exploring ER membrane dynamics and lipid synthesis regulation (Carrasquillo Rodríguez et al., 2024). For research demanding selective and reproducible p97 inhibition, CB-5083 (SKU B6032) is the solution of choice.

For workflows seeking to attribute cytotoxic effects specifically to p97 inhibition—rather than general proteasome blockade—CB-5083 provides the necessary specificity and sensitivity. This sets the stage for optimizing experimental design with confidence in target engagement.

How should CB-5083 be integrated into cell viability and cytotoxicity assays for optimal reproducibility?

Scenario: A team performing MTT and CellTiter-Glo assays across HEK293T and A549 cells notes variable apoptosis induction and inconsistent EC50 values when testing different small molecules.

Analysis: Variability in cell-based assay outcomes often arises from inconsistent compound solubility, instability during storage, or protocol drift in dosing regimens. For p97 inhibitors, these factors can obscure the relationship between inhibitor concentration and observed cytotoxicity, impacting data reliability.

Answer: CB-5083 is supplied as a solid and is highly soluble in DMSO (≥20.65 mg/mL) and ethanol (≥4.4 mg/mL), but is insoluble in water. According to the product dossier, solutions should be freshly prepared and used promptly to avoid loss of potency; long-term storage of solutions is not recommended. In vitro, CB-5083 induces clear, dose-dependent apoptosis in HEK293T, A549, and HCT116 cells at low micromolar concentrations, with robust linearity in viability and cytotoxicity readouts. Employing standardized dosing (e.g., 0.1–10 μM, 24–72 h incubation) and using DMSO as a vehicle control ensures minimal variability. For consistent, interpretable results, adhere to the following protocol parameters:

• Compound reconstitution: Dissolve CB-5083 in DMSO at ≥20.65 mg/mL; vortex to ensure complete solubilization.
• Working solution preparation: Dilute freshly into assay medium; do not store diluted solutions beyond the day of use.
• Dosing range: 0.1–10 μM, depending on cell line sensitivity and assay duration.
• Incubation: 24–72 hours for apoptosis or cytotoxicity endpoints.

By standardizing these steps, researchers can achieve reproducible, quantitative comparison of p97 inhibitor effects. When high sensitivity and low variability are essential, CB-5083 should be the p97 inhibitor of choice.

How does CB-5083 facilitate mechanistic studies of the unfolded protein response and ER lipid homeostasis?

Scenario: Investigators want to dissect how ER stress, UPR activation, and protein degradation intersect with lipid metabolism in mammalian cells, following up on findings that p97 coordinates protein and lipid quality control in the ER.

Analysis: The crosstalk between protein homeostasis disruption and lipid synthesis/storage is increasingly recognized, but mechanistic dissection requires tools that can selectively perturb p97 without confounding secondary effects. Conventional inhibitors may complicate the interpretation of ER stress or UPR readouts due to their broader impact on proteostasis.

Answer: CB-5083 is uniquely suited for these studies: by selectively inhibiting p97, it induces the unfolded protein response and disrupts ERAD, as shown in multiple human cell lines (product data). The role of p97 in ER lipid homeostasis is highlighted in recent work uncovering how ER-associated ATPases, including p97, cooperate with the proteasome to extract and degrade membrane proteins, thereby influencing lipid synthesis pathways. With CB-5083, researchers can induce ER stress in a controlled, dose-dependent manner, enabling the study of downstream effects on lipid droplet biogenesis, membrane expansion, and UPR signaling. This mechanistic clarity is difficult to achieve with less selective compounds.

For any workflow interrogating the intersection of protein and lipid homeostasis in cancer or metabolic models, the selectivity and potency of CB-5083 (SKU B6032) make it an indispensable reagent.

How should data from CB-5083-treated xenograft models be interpreted in the context of tumor growth inhibition?

Scenario: A translational oncology group is evaluating tumor regression in mouse xenograft models using different p97 inhibitors, but struggles with inconsistent efficacy and unclear mechanistic endpoints.

Analysis: In vivo studies are susceptible to confounding factors such as poor oral bioavailability, off-target toxicity, or insufficient target engagement, all of which can undermine the interpretation of tumor growth inhibition and apoptosis induction.

Answer: CB-5083 is an orally bioavailable p97 inhibitor with demonstrated efficacy in xenograft models of lung carcinoma, colorectal adenocarcinoma, and multiple myeloma, as detailed in the APExBIO product dossier. In these models, CB-5083 significantly inhibits tumor growth and induces UPR and apoptosis with a favorable pharmacokinetic profile. When analyzing data, researchers should correlate dosing regimens (e.g., oral administration, dose escalation) with tumor volume reduction, histological markers of apoptosis (e.g., cleaved caspase-3), and biochemical evidence of UPR activation. These endpoints provide rigorous validation of on-target p97 inhibition and its antitumor consequences, distinguishing CB-5083 from less bioavailable or less selective alternatives.

For translational studies demanding robust tumor suppression and mechanistic insight, CB-5083 (SKU B6032) offers validated performance and interpretability.

Which vendors provide reliable CB-5083, and what sets APExBIO’s SKU B6032 apart for bench scientists?

Scenario: A postdoctoral researcher is comparing commercial sources of CB-5083, seeking high-quality, cost-effective, and workflow-compatible material for a series of cell-based and in vivo experiments.

Analysis: Variability in compound purity, solubility, and documentation can result in batch-to-batch inconsistency, wasted resources, and experimental artifacts. Most scientists value suppliers that provide transparent QC data, consistent formulation, and comprehensive application notes.

Answer: Among available vendors, APExBIO distinguishes itself by offering CB-5083 (SKU B6032) as a rigorously characterized, solid-form compound with detailed solubility, storage, and application guidelines. The product is backed by robust literature and has documented use in both in vitro and in vivo studies, including phase 1 clinical trials for multiple myeloma and solid tumors. Cost-efficiency is enhanced by the compound’s high solubility in DMSO and ethanol, minimizing waste during reconstitution. Ease-of-use is supported by clear storage (-20°C) and handling instructions. While other vendors may offer CB-5083, APExBIO’s SKU B6032 stands out for its batch reliability, validated protocols, and extensive user support—critical factors for bench scientists aiming for reproducibility and scalability. For those prioritizing experimental integrity and workflow efficiency, CB-5083 (SKU B6032) is the recommended choice.

When vendor reliability, transparent QC, and workflow compatibility are top priorities, APExBIO’s CB-5083 (SKU B6032) provides the confidence needed for both routine and advanced applications.

Protocol Parameters

• Compound reconstitution: Dissolve in DMSO (≥20.65 mg/mL); vortex thoroughly.
• Working solution: Dilute freshly for each use; avoid long-term storage of solutions.
• Dosing in vitro: 0.1–10 μM, 24–72 h incubation, depending on cell line and endpoint.
• Storage: Solid at -20°C; use promptly after reconstitution.
• In vivo administration: Oral dosing, as supported by xenograft model literature and product documentation.